Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in Hemodialysis patients

被引:14
|
作者
Fiedler, R
Deuber, HJ
Langer, T
Osten, B
Mohan, S
Jehle, PM
机构
[1] Univ Halle Wittenberg, Div Nephrol, Dept Nephrol, DE-06097 Halle An Der Saale, Germany
[2] KfH Dialysis Ctr, Zirndorf, Germany
[3] St Elizabeth Hosp, Dept Internal Med 1, Halle An Der Saale, Germany
[4] Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr 151, Loma Linda, CA 92354 USA
[5] Paul Gerhardt Fdn Hosp, Lutherstadt Wittenberg, Germany
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 96卷 / 01期
关键词
reduced dialysate calcium; calcium-phosphorus product; parathyroid hormone; noninvasive bone markers; IGF system components;
D O I
10.1159/000075565
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The safety of using reduced calcium dialysate (RDC) in hemodialysis (HD) patients is controversial due to related changes in bone metabolism. In the present study we investigated whether an 18-month treatment period with RDC may induce significant changes in calcium-phosphorus product (CaxP), bone metabolism, and components of the insulin-like growth factor (IGF) system in HD patients. Study Design: In this prospective study, 13 HD patients with biochemical signs of diminished or low-normal bone turnover and high CaxP due to high serum calcium level were treated by lowering dialysate calcium from 3.5 to 2.5 mEq/l for 18 months. By specific immunometric assays, serum levels of intact parathyroid hormone (PTH), bone alkaline phosphatase (B-ALP), pyridinoline (PYR), desoxypyridinoline (D-PYR), 25-OH-vitamin D-3 (25-vit D-3), 1,25-(OH)(2)-vitamin D-3 (1,25-vit D-3), free IGF-I, IGF-II, and IGF-binding protein (IGFBP)-1 to -6 were measured. Results: CaxP decreased significantly from 5.62 (baseline) to 3.95 mmol(2)/l(2) (at 18 months), whereas PTH increased from 81 +/- 57 pg/ml at baseline to 236 +/- 188 at 12 months (p < 0.01), remaining in this range thereafter. Parameters of bone resorption (PYR) as well as formation (B-ALP) significantly increased during RDC, with peak levels after 12 months. Despite increasing doses of oral alfacalcidol, levels of 25-vit D-3 and 1,25-vit D-3 subsequently declined during RDC. In parallel with the changes in bone markers, free IGF-I levels decreased (baseline: 1.9 +/- 0.9 ng/ml, after 18 months: 1.1 +/- 0.7; p < 0.01). The decline of free IGF-I correlated with decreasing levels of IGFBP-3 and increasing levels of IGFBP-1/-4. Conclusion: The treatment with RDC effectively lowered CaxP and stimulated bone formation and resorption. The different changes in bone markers and IGF system components mirror the complex effects on bone metabolism. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C3 / C9
页数:7
相关论文
共 50 条
  • [1] Calcium-phosphorus metabolism in patients on daily hemodialysis: Comparison to conventional hemodialysis.
    Castro, MCM
    Luders, C
    Abensur, H
    Ferraboli, R
    Elias, RM
    Romao, JE
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 411A - 411A
  • [2] Impact of current management of phosphorus, calcium, calcium-phosphorus product and parathyroid hormone in hemodialysis patients.
    Ouseph, R
    Jacobs, AA
    Brier, ME
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 269A - 269A
  • [3] CORRELATION OF CALCIUM-PHOSPHORUS METABOLISM & CARDIAC STRUCTURE IN MAINTENANCE HEMODIALYSIS PATIENTS
    Xu, Tao
    Peng, Bin
    Wang, Niansong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 654 - +
  • [4] Bone mineral density and calcium-phosphorus metabolism in patients with underweight
    Tsagareli, M.
    Giorgadze, E.
    Asatiani, K.
    Bochorishvili, K.
    Tsagareli, N.
    Bestavashvili, I.
    Sulikashvili, T.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S171 - S171
  • [5] CALCIUM AND PHOSPHORUS-METABOLISM IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS WITH DIFFERENT CALCIUM CONCENTRATIONS IN THE DIALYSATE
    KOVARIK, J
    GRAF, H
    STUMMVOLL, HK
    WOLF, A
    PINGGERA, W
    WIENER KLINISCHE WOCHENSCHRIFT, 1979, 91 (22) : 765 - 768
  • [6] Effects of reduced lower calcium dialysate (LCD) in hemodialysis patients
    Lee, YS
    Kim, SJ
    Kang, DH
    Yoon, KI
    Choi, KB
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V92 - V92
  • [7] The fallacy of the calcium-phosphorus product
    O'Neill, W. C.
    KIDNEY INTERNATIONAL, 2007, 72 (07) : 792 - 796
  • [8] MODIFICATIONS OF CALCIUM-PHOSPHORUS METABOLISM IN PATIENTS WITH CHRONIC RENAL INADEQUACY SUBJECT TO HEMODIALYSIS PROGRAMS
    PEREZRUILOPEZ, MA
    DAMIANORIVERO, A
    HERRERIASECHABE, JM
    GARRIDOPERALTA, M
    REVISTA IBERICA DE ENDOCRINOLOGIA, 1976, 23 (138): : 535 - &
  • [9] CALCIUM-PHOSPHORUS PRODUCT AND METASTATIC CALCIFICATION
    HSU, CH
    SEMINARS IN DIALYSIS, 1994, 7 (05) : 373 - 373
  • [10] Calcium-phosphorus Metabolism In Patients With Cushing's Disease
    Povaliaeva, Alexandra
    Pigarova, Ekaterina
    Zhukov, Artem
    Dzeranova, Larisa
    Nikankina, Larisa
    Rozhinskaya, Liudmila
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 56 - 57